Capricor Therapeutics Faces Securities Lawsuits
Analysis based on 40 articles · First reported Jul 21, 2025 · Last updated Sep 03, 2025
The denial of the Biologics License Application by the United States — Food and Drug Administration for Paragon Therapeutics' lead drug candidate caused a significant decline in Paragon Therapeutics' stock price. This event has led to multiple law firms, including Rosen Law Firm, The Gross Law Firm, and Levi & Korsinsky, filing class action lawsuits, creating negative sentiment for Paragon Therapeutics and potentially impacting investor confidence in the biotechnology sector.
Paragon Therapeutics is facing multiple class action lawsuits from law firms including Rosen Law Firm, The Gross Law Firm, and Levi & Korsinsky, following a significant drop in its stock price. The lawsuits allege that Paragon Therapeutics provided misleading statements and concealed material adverse facts regarding its lead cell therapy candidate drug, deramiocel, for Duchenne muscular dystrophy. On July 11, 2025, the United States — Food and Drug Administration issued a Complete Response Letter, denying Paragon Therapeutics' Biologics License Application for deramiocel, citing a lack of substantial evidence of effectiveness and issues with Chemistry, Manufacturing, and Controls. This news caused Paragon Therapeutics' stock to decline from $11.40 to $7.64 per share. Investors who purchased shares between October 9, 2024, and July 10, 2025, are encouraged to join the class action, with a lead plaintiff deadline of September 15, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard